![]() ![]() After many years of research since the discovery of CA19-9, a biomarker validated to perform better than CA19-9 for pancreatic cancer detection is not yet available. 4 Therefore, CA19-9 represents an important marker for pancreatic cancer and a good basis on which to build molecular indicators for cancer, but it needs to be improved. However, the test is very specific for cancer at high cut-off values. By using a typical cut-off value of 37 U/mL, approximately 25%–35% of patients do not show increases, 4 rendering the test inconclusive for the diagnosis or monitoring of cancer in many patients. 3 The test is used as an approximate indicator of extent of disease recurrence, but a problem with CA19-9 is that it is not increased in a substantial proportion of patients. ![]() 1, 2 The sLeA glycan forms the basis for the Food and Drug Administration–approved cancer antigen 19-9 (CA19-9) test, named after the monoclonal antibody first developed against the sLeA antigen. Many pancreatic cancers secrete glycoproteins and glycolipids that bear a glycan called sialyl-Lewis A (sLeA). The detection of a 3-biomarker panel of glycans resulted in improved diagnostic accuracy over CA19-9. This article reports that glycan biomarkers related to CA19-9 are increased in subsets of pancreatic cancer patients with prevalence similar to CA19-9. ![]() The cancer antigen 19-9 (CA19-9) blood test is a useful biomarker for pancreatic cancer in certain situations but is not increased in a substantial percentage of patients. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |